SCIB1: Phase I/II halted

Scancell suspended dosing in the open-label, dose-escalation, U.K. Phase I/II SCIB1-001 trial evaluating up to 8 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24 after the company’s analysis o...